



A novel method for harvesting concentrated platelet-rich fibrin (C-PRF) with a 10-fold increase in platelet and leukocyte yields

Richard J. Miron^{1,2} · Jihua Chai¹ · Peng Zhang¹ · Yuqing Li¹ · Yunxiao Wang¹ · Carlos Fernando de Almeida Barros Mourão³ · Anton Sculean² · Masako Fujioka Kobayashi⁴ · Yufeng Zhang^{1,5}

Received: 10 September 2019 / Accepted: 6 November 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract

Background and objectives Liquid platelet rich fibrin (PRF; often referred to as injectable PRF) has been utilized as an injectable formulation of PRF that is capable of stimulating tissue regeneration. Our research group recently found that following standard L-PRF protocols (2700 RPM for 12 min), a massive increase in platelets and leukocytes was observed directly within the buffy-coat layer directly above the red blood cell layer. The purpose of this study was to develop a novel harvesting technique to isolate liquid PRF directly from this buffy coat layer and to compare this technique to standard i-PRF.

Materials and methods Standard high g-force L-PRF and low g-force i-PRF protocols were utilized to separate blood layers. Above the red blood corpuscle layer, sequential 100- μ L layers of plasma were harvested (12 layers total; i.e., 1.2 mL, which represents the total i-PRF volume), and 3 layers ($3 \times 100 \mu$ L) were harvested from the red blood cell layer to quantify blood cells. Each layer was then sent for complete blood count (CBC) analysis, and the cell numbers were quantified including red blood cells, leukocytes, neutrophils, lymphocytes, monocytes, and platelets. The liquid PRF that was directly collected from the buffy-coat layer following L-PRF protocols was referred to as concentrated PRF (C-PRF).

Results The i-PRF protocol typically yielded a 2- to 3-fold increase in platelets and a 1.5-fold increase in leukocyte concentration from the 1- to 1.2-mL plasma layer compared to baseline concentrations in whole blood. While almost no cells were found in the first 4-mL layer of L-PRF, a massive accumulation of platelets and leukocytes was found directly within the buffy coat layer demonstrating extremely high concentrations of cells in this 0.3–0.5-mL layer (~ 20-fold increases). We therefore proposed harvesting this 0.3- to 0.5-mL layer directly above the red blood cell corpuscle layer as liquid C-PRF. In general, i-PRF was able to increase platelet numbers by ~ 250%, whereas a 1200–1700% increase in platelet numbers could easily be achieved by harvesting this 0.3–0.5 mL of C-PRF (total platelet concentrations of $> 2000\text{--}3000 \times 10^9$ cells/L).

Conclusion While conventional i-PRF protocols increase platelet yield by 2-3-fold and leukocyte yield by 50%, we convincingly demonstrated the ability to concentrate platelets and leukocytes over 10-fold by harvesting the 0.3–0.5 mL of C-PRF within the buffy coat following L-PRF protocols.

Clinical relevance Previous studies have demonstrated only a slight increase in platelet and leukocyte concentrations in i-PRF. The present study described a novel harvesting technique with over a 10-fold increase in platelets and leukocytes that can be further utilized for tissue regeneration.

Keywords Fibrin · Blood platelets · Wound healing · Platelet-rich fibrin

Richard J. Miron and Jihua Chai contributed equally to this work.

✉ Richard J. Miron
richard.miron@zmk.unibe.ch

¹ The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, China

² Department of Periodontology, University of Bern, Bern, Switzerland

³ Department of Oral Surgery, Dentistry School, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil

⁴ Department of Maxillofacial Surgery, Inselspital, University of Bern, Bern, Switzerland

⁵ Department of Dental Implantology, School and Hospital of Stomatology, Wuhan University, Wuhan, China

Introduction

Platelet concentrates have been utilized in dentistry and medicine for over three decades due to their ability to release supra-physiological doses of autologous growth factors [1, 2]. Platelet-rich plasma (PRP) was first developed for use in regenerative dentistry, but its use is also widespread in maxillofacial surgery, orthopedic surgery, and esthetic medicine due to its ability to rapidly stimulate tissue neoangiogenesis [3–7]. Proper protocols utilizing PRP typically involve the use of anticoagulants and high g-forces to selectively layer blood cells based on density. Due to these high g-forces, a top platelet-poor layer (acellular) is typically produced within the upper layer, followed by a platelet-rich layer (buffy coat; middle layer), and a bottom red blood cell (corpuscle) layer. Since anticoagulants are utilized, cell layers are separated without fear of coagulation, and typical centrifugation cycles typically range from 15 min to 1 h. Despite the success of PRP, various concerns have been raised due to their use of anticoagulants which have been shown to negatively impact tissue regeneration [3, 8, 9].

Platelet-rich fibrin (PRF) was therefore developed with the aim of removing anticoagulants [10]. As a result, the spin cycles are typically much shorter. Following centrifugation, a three-dimensional fibrin matrix is produced that may serve as a tissue engineering scaffold for various medical procedures that necessitate either soft- or hard-tissue regeneration [11–13]. In dentistry alone, PRF has been utilized for the treatment of extraction sockets [14–17], gingival recessions [18–20], palatal wound closure [21–23], the regeneration of periodontal defects [24], and hyperplastic gingival tissues [25]. In other medical fields, PRF has been utilized for the successful management of hard-to-heal leg ulcers, including diabetic foot ulcers, venous leg ulcers, and chronic leg ulcers [26]. The reported advantages include faster healing, increases in angiogenesis, lower costs (when compared to PRP), and complete immune biocompatibility [27–30].

By utilizing even shorter centrifugation cycles and by modifying the centrifugation tubes, our group demonstrated the advantages of an injectable PRF (termed i-PRF) compared to PRP [31]. Furthermore, a number of studies have further demonstrated that the cellular activity of i-PRF is superior to that of PRP [31–34].

Recently, our research group developed a novel technique to quantify cells within platelet concentrates following centrifugation by sequentially pipetting 1-mL layers of blood following centrifugation [35]. This highly effective quantification method reveals the exact concentration/location of various blood cells following centrifugation and allows a direct investigation of PRF protocols based on the final cell composition. Surprisingly, following L-PRF protocols, a large number of cells accumulated within the buffy coat directly above the red blood cell layer (1-mL sample), with very few cells

found throughout the upper PRF clot [35]. We therefore aimed to address two specific questions in the current study: (1) What was the total volume above the red blood corpuscle layer and within the buffy coat in which the majority of these cells were located; and (2) what final concentration of platelets and leukocytes could be harvested by selectively collecting the cells found within this “buffy-coat” region when compared to conventional i-PRF protocols.

Materials and methods

Preparation of PRF


Blood samples were collected with the informed consent of six volunteer donors. All procedures performed in this study involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. No internal review board (IRB) was required for this study because the human samples were not identified [31]. The factors that affect fibrin clot formation and structure include genetic factors, acquired factors (such as an abnormal concentration of thrombin and factor XIII in the plasma, blood flow, platelet activation, oxidative stress, hyperglycemia, hyperhomocysteinemia, medications, and cigarette smoking), and other parameters (such as microgravity, pH, temperature, reducing agents, and the concentration of chloride and calcium ions) [36]. All patients with any of the above conditions were excluded. All included patients were systemically healthy, nonsmoking, and not taking any medications.

The following two centrifugation devices were utilized in this study: an IntraSpin Device (IntraLock, Boca Raton, Florida, USA) and a Duo Quattro (Process for PRF, Nice, France). Two separate protocols were tested. On the Intraspin device, an ~ 700 RCF-max (~ 400 RCF-clot) for 12 min was utilized for the L-PRF protocol, whereas an ~ 60 RCF-max for 3 min was utilized for the i-PRF protocol.

Each of the six volunteers donated three blood collection tubes (10-mL plastic tubes) for each of the two test groups, for a total of six tubes per participant. Additionally, one blood sample was collected to quantify control whole blood. Specific plastic hydrophobic tubes (Chixin Biotech, Wuhan, China) were utilized to prevent clotting during centrifugation.

For one participant, an additional two tubes were harvested to demonstrate the general location of cells following centrifugation using the L-PRF and i-PRF protocols by utilizing the previously proposed 1-mL sequential pipetting method [35] (presented in Figs. 1a and 2). Since we previously observed a massive accumulation of cells within the buffy layer in a 1-mL sample range following the L-PRF protocol, we aimed to precisely investigate the volume in which these cells were located

Fig. 1 (a) Illustration demonstrating the proposed novel method to quantify cell types following centrifugation. Currently, one limitation reported with standard quantification methods is that whole blood is compared to the total plasma concentration following centrifugation. This, however, does not give a proper representation of the location of cells following centrifugation. By utilizing the proposed technique in this study and sequentially pipetting a 1-mL volume from the top layer moving downwards, it is possible to perform CBC analysis on each of the 10 samples and to accurately determine the precise location of each cell type following centrifugation with various protocols. One layer (in this case, layer 5) will contain some yellow plasma and red blood cells. This is typically the location of the buffy coat, where a higher concentration of platelets/leukocytes is typically located. **(b)** The concentration of the cell types in each layer from 1 mL down to the 10th milliliter sample utilizing the L-PRF protocol (2700 RPM for 12 min; ~ 700 g). The majority of platelets, leukocytes, and monocytes accumulated in the fifth layer of the buffy coat. The first four layers of this plasma layer were typically devoid of all cells. Reprinted with permission [35]




within this 1-mL layer directly above the red cell corpuscle layer. Thus, we developed a novel methodological approach in which 100- μ L sequential layers were pipetted starting from ~ 1.2- to 1.5-mL layers above the buffy coat, until reaching the red blood cell layer (Figs. 3a and 4a, depicted as the + 1 to + 12 layer). Additionally, three layers were harvested from the red blood cell layer to determine the number of cells in this layer (Figs. 3a and 4a, depicted as the - 1 to - 3 layer). Each of these 100- μ L layers was sent for CBC analysis.

The second tube from each group was utilized to determine the final concentration from the liquid version of the i-PRF yellow plasma layer and compared to those from the average

sequential 100- μ L layers. For L-PRF protocols, one tube was utilized to harvest 0.5 mL of concentrated PRF (defined as the 0.5-mL buffy coat directly above the red blood corpuscle). This layer is referred to as concentrated PRF (C-PRF) throughout this article because it was harvested from the concentrated buffy-coat layer. Similarly, 0.3 mL of C-PRF liquid was harvested from this layer as well. The blood draw for the 100- μ L sequential analysis was carried out with anticoagulants to allow blood samples to be sent for CBC analysis, during which the total number of leukocytes, red blood cells, platelets, neutrophils, lymphocytes, and monocytes was determined in each sample. Thereafter, the data from each sample

Fig. 2 The concentration of the cell types in each layer from 1 mL down to the 10th milliliter sample from the injectable i-PRF protocol (800 RPM for 3 min; ~ 60 g). There was very little change in the platelet or leukocyte accumulation utilizing this centrifugation protocol. However, a slight increase in platelets and leukocytes was observed in the upper 1–2-mL layers compared to the control



were displayed graphically using GraphPad Prism 8.0 software and were analyzed with one-way ANOVA (GraphPad Software, Inc., La Jolla, CA, USA).

Results

Comparison of cell separation following centrifugation of L-PRF and i-PRF


First, a novel method to investigate cell types following centrifugation utilizing 1-mL sequential pipetting was used to investigate which layers contained the various cell types following centrifugation at both high (L-PRF) and low (i-PRF) g forces (Figs. 1b and 2). Interestingly, in the L-PRF protocol, the majority of platelets and leukocytes (monocytes and lymphocytes) accumulated in layer 5, representing the buffy coat transition between the plasma layer and red blood cell layer.

Within this layer, a general 3- to 5-fold increase in the cell concentration was observed compared to that in the control whole blood sample (Fig. 1b). In contrast, the i-PRF protocol demonstrated an average 1.5- to 2.5-fold increase in the various cell types in layers 1–2 (Fig. 2). Since the i-PRF protocol generated a higher concentration of platelets and leukocytes than the L-PRF protocol (because the i-PRF volume was ~ 1–1.3 mL vs the 4.5–5 mL volume in L-PRF), we therefore sought to precisely collect the layer within the buffy coat of the L-PRF protocol (zone 5), where a massive increase in cell numbers was observed directly within the buffy coat.

Sequential pipetting of 100- μ L layers in i-PRF and L-PRF

The first question that our group aimed to address was the total volume of the cell-rich liquid above the buffy coat in which platelets and leukocytes were located following the L-PRF


Fig. 3 (a) A second methodological illustration depicting the sequential harvesting technique. Briefly, as the majority of cells were found to accumulate within 1 mL of the buffy coat, we sought to precisely investigate the total volume of liquid (mL) above the buffy coat in which cells were concentrated. Following the L-PRF protocol, the upper 3.5 mL was removed, followed by sequential 100- μ L layer pipetting and CBC analysis. Three layers of the red blood cell layer were also harvested. **b** The concentration of the cell types in each of the 12 layers (100 μ L each) above the red blood cell layer following the L-PRF protocol. There was a massive increase in platelets (roughly a 20-fold increase specifically at the buffy coat layer, between the yellow and red blood cell layers). Interestingly, all cells seemed to accumulate within 3–5 layers (300–500 μ L) above the red blood corpuscle



protocol. To address this question, the first 3.5 mL of the upper-plasma layer was removed (acellular layer) from the tube (leaving 1.0–1.5 mL of sample above the red blood cell layer). Thereafter, a sequential pipetting method was once again utilized again from the top down with sequential 100- μ L layers to accurately determine how many layers above

the red cell layer contained cells (Fig. 3a). Furthermore, 300 μ L of the red blood corpuscle layer was also harvested and quantified in 100- μ L sequential layers (Fig. 3a). In contrast, the entire i-PRF layer was collected starting from the upper 100- μ L layer and was sequentially pipetted until all the plasma layers were collected (Fig. 4a). Once again, 300 μ L was

Fig. 4 (a) A second methodological illustration depicting the sequential harvesting technique. Similar to L-PRF, all plasma layers of the i-PRF protocol were also harvested in 100- μ L sequential layers. Three red blood cell layers (100 μ L each) were also collected. (b) The concentration of cell types in each layer from 100- μ L layers in i-PRF and three layers in the red cell layer. A typical 2–3-fold increase in platelets was observed, whereas only a slight increase in leukocytes and other cell types was observed directly at the separating layer between the plasma and red blood cell layers



sequentially pipetted in 100- μ L layers from the red blood corpuscle layer.

Figure 4b demonstrates the results from the sequential 100- μ L layers in the i-PRF protocol. In layer 13, there was a 3-fold increase (from 5 to 15×10^9 cells/L) in leukocytes directly at buffy-coat layer 13 (represented by arrows). There was also a 5- to 6-fold increase in monocytes. Following the i-PRF protocol, a 2.5-fold increase (from a

baseline of ~ 220 to $\sim 550 \times 10^9$ platelets/L) in platelets in all 13 layers (1.3 mL, i.e., thirteen 100- μ L samples) was observed, with only a slight increase in leukocyte concentrations.

In contrast, Fig. 3b shows the results from the sequential 100- μ L layers above the red blood layer that were found following the L-PRF protocol. Interestingly, almost all the cells accumulated within three layers (i.e., 300 μ L) above the red blood corpuscle (Fig. 3b). Most

surprisingly, within this layer, a massive increase in platelets, monocytes, leukocytes, and lymphocytes was observed. For instance, an increase from 225 to 6000 × 10⁹ platelets/L was observed, representing a > 25-fold increase in the platelet concentration compared to that at baseline; this specifically occurred within 100 μL above the red blood cell layer.

Based on these results, we assumed that a 0.3- to 0.5-mL layer of concentrated PRF (C-PRF) could be preferentially collected within this buffy coat directly above the red cell layer (Fig. 5a). Figure 5b demonstrates that while the i-PRF protocol increases the leukocyte numbers 1.23-fold, a marked and significant increase in the leukocyte concentration was observed (4.62- and 7.34-fold increases) in both the 0.5-mL and 0.3-mL C-PRF, respectively. Even more strikingly, while i-PRF protocols have typically been shown to increase platelet yields between 200 and 300%, the C-PRF protocols massively increased platelet yields 1138% and 1687%, respectively (Fig. 5c). A similar trend was also observed for monocytes (Fig. 5d). The total after averaging the data from six patients are summarized in Table 1.

Table 1 Properties of blood cells

| | Platelets | WBC | RBC |
|------------------------------|----------------|-----------|-----------|
| Density (kg/m ³) | 1040–1065 | 1055–1085 | 1095–1100 |
| Frequency (1/μL) | 200,000 | 5000 | 5,000,000 |
| Surface (μm ²) | 28 | 330 | 140 |
| Radius (μm) | 11.5 | 5–7.5 | 4 |
| Volume (μm ³) | 14 | 200 | 92 |
| Shape | Irregular disk | Spherical | Biconcave |

Discussion

From approximately 2014–2016, the low speed centrifugation concept (also referred to as the LSCC) was believed to isolate the maximum number of cells and the most growth factors following centrifugation due to the reduced relative g-force applied during centrifugation (i.e., less cells were pushed towards the bottom of the centrifugation tubes). When investigating full-sized PRF membranes or plasma layers, this proved to be true and has been confirmed in numerous studies since [37–40]. Furthermore, our group further demonstrated that centrifugation that utilized lower centrifugation speeds




Fig. 5 (a) Proposed method to harvest concentrated PRF (C-PRF). Following L-PRF protocols, since all cells accumulated within 300–500 μL above the red cell layer, it was proposed to collect 0.3–0.5 mL of the liquid C-PRF directly above the red cell junction to obtain a liquid plasma layer with highly concentrated platelets and leukocytes. (b–d) Concentration of (b) leukocytes, (c) platelets, and (d) monocytes

following centrifugation using i-PRF protocols versus the collection of 0.3–0.5 mL of concentrated PRF (C-PRF). While i-PRF could typically achieve a 1.2- to 2.5-fold increase in the various cell types following centrifugation, up to a 15-fold increase in the platelet concentration could be achieved with C-PRF. (* represents a significant difference compared to i-PRF; ** represents significantly higher than all groups, *p* < 0.05)

(now termed advanced PRF) released higher levels of total growth factors, such as PDGF, TGF- β 1, VEGF, EGF, and IGF, compared to control L-PRF [41, 42].

The findings from the present study represent a shift in our understanding of liquid PRF and the ability to concentrate platelets and leukocytes for liquid injectable use. Previously, work comparing i-PRF and PRP conducted by our group found similar levels of growth factor release between the two protocols, with little understanding of the previously observed results. The findings from the present study represent a breakthrough in understanding the differences reported between PRP, i-PRF, and C-PRF with regard to platelet yields. Many clinicians believe that platelet yields upwards of 1500×10^9 cells/L are ideal for regenerative purposes, yet i-PRF protocols were typically found to isolate cells within the concentration range of $500\text{--}600 \times 10^9$ cells/L, and many clinicians deemed this concentration too low. One of the main advantages of i-PRF is that due to its lack of anticoagulants, clotting occurs shortly following injection or during mixing with biomaterials, thus favoring a longer and more gradual release of growth factors over time compared to PRP [41]. Nevertheless, a comparative study between i-PRF and PRP demonstrated very similar growth factor release over time, with some growth factors being released more in i-PRF, whereas others were released in higher levels in PRP [31].

Over the past few months, a sequential pipetting methodology was developed to accurately quantify the effect of centrifugation protocols on the separation of cell layers. This method was developed to accurately identify the location of cells following various centrifugation protocols. While A-PRF protocols, which involve centrifugation at 200 RCF-max (as opposed to 700 in L-PRF protocols), have been shown to more evenly distribute platelets in the upper 4-mL layers of plasma [35], it was interesting to note that a massive accumulation of platelets and leukocytes was observed directly above the red blood cell layer following L-PRF protocols. We therefore aimed to investigate (1) in what volume the majority of these cells were located and (2) what was the maximum concentration of leukocytes and platelets in PRF that could be obtained by harvesting this specific concentrated region of cells (C-PRF).

One of the surprising findings was how concentrated the various cells were in the buffy coat directly above the red blood cell layer following L-PRF protocols. In all samples, cells were routinely situated within 0.3–0.5 mL above the red blood cell corpuscle, with the great majority located 0.1–0.2 mL within the buffy coat above the red blood cell layer. Notably, a large number of leukocytes and monocytes were located in the first 100- μ L red blood cell layer, and it will be interesting to determine whether this 100 μ L of red blood cells should be collected and included within liquid-PRF formulations due to its large incorporation of various white blood cells. In contrast, although L-PRF has also been referred to

as “leukocyte” and platelet-rich fibrin (i.e., L-PRF), it is interesting to note that the leukocyte concentration in L-PRF is actually lower than that what is found in standard whole blood [35]. This means that following the centrifugation protocol to produce L-PRF clots, an actual decrease in leukocyte numbers is observed [35]. The protocol with the greatest ability to concentrate leukocytes (i-PRF) only increases their concentration by approximately 50%. Within the present study, we demonstrated for the first time an ability to concentrate leukocytes between 500 and 750% compared to the concentrations in whole blood by utilizing the C-PRF harvesting method outlined in this study. We also demonstrated the ability to concentrate platelets over 15-fold compared to baseline, whereas i-PRF protocols only concentrate platelets by 2–3-fold (Table 1; Fig. 5). To the best of these authors’ knowledge, this is the highest concentration of both platelets and leukocytes observed to date in any PRF preparation.

One interesting phenomenon left to investigate is the possibility of further optimizing the C-PRF protocol. In general, L-PRF protocols are known to concentrate the majority of leukocytes and other white blood cells (greater than 50%) in the red blood cell layer (not included in the PRF layer). Therefore, it would be interesting to further evaluate whether a better yield of platelets and leukocytes could be obtained by further modifying the centrifugation protocols. Another interesting recent development has been the improvements in the ability to separate cell layers (based on density) using a horizontal centrifuge which resulted in up to a 4-fold increase in cell concentrations [35]. Future studies comparing horizontal centrifugation versus fixed-angle centrifugation for the harvesting of C-PRF is therefore needed. In summary, the findings from the present study report the development of a novel method to harvest the enriched portion (more platelets/leukocytes) directly from the liquid layer directly above the red blood cell layer within the buffy coat for the collection of a liquid injectable PRF highly rich in platelets and leukocytes.

Conclusion

The present study describes a novel technique for investigating the cell accumulation directly above the red blood cell layer within the buffy coat. A massive accumulation of leukocytes, platelets, and monocytes was located specifically within this 0.3- to 0.5-mL layer when utilizing high g-force protocols (L-PRF). While conventional i-PRF protocols are able to concentrate leukocytes up to 1.5-fold and platelets 2–3-fold, we demonstrated that there was a > 500% increase in leukocytes and a > 1500% increase in platelets when utilizing this novel concentrated PRF (C-PRF) harvesting technique. Further comparative preclinical and clinical studies are now needed to examine the added regenerative potential of C-PRF compared to conventional i-PRF protocols.

Funding information This work was supported by funds from the National Key R&D Program of China (2018YFC1105300 to Yufeng Zhang).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflicts of interest.

Ethical approval No ethical approval was required for this study, as the human samples were not identified.

Informed consent For this study, informed written consent was provided to conduct the outlined experiments prior to the blood draw.

References

- Chow TW, McIntire LV, Peterson DM (1983) Importance of plasma fibronectin in determining PFP and PRP clot mechanical properties. *Thromb Res* 29:243–248
- Delaini F, Poggi A, Donati MB (1982) Enhanced affinity for arachidonic acid in platelet-rich plasma from rats with Adriamycin-induced nephrotic syndrome. *Thromb Haemost* 48:260–262
- Marx RE (2004) Platelet-rich plasma: evidence to support its use. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons* 62: 489–496
- Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR (1998) Platelet-rich plasma: growth factor enhancement for bone grafts. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 85:638–646
- Cai YZ, Zhang C, Lin XJ (2015) Efficacy of platelet-rich plasma in arthroscopic repair of full-thickness rotator cuff tears: a meta-analysis. *Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons [et al]* 24:1852–1859. <https://doi.org/10.1016/j.jse.2015.07.035>
- Meheux CJ, McCulloch PC, Lintner DM, Varner KE, Harris JD (2016) Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. *Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association* 32:495–505. <https://doi.org/10.1016/j.arthro.2015.08.005>
- Singh B, Goldberg LJ (2016) Autologous Platelet-Rich Plasma for the Treatment of Pattern Hair Loss. *Am J Clin Dermatol*. <https://doi.org/10.1007/s40257-016-0196-2>
- Anfossi G, Trovati M, Mularoni E, Massucco P, Calcamuggi G, Emanuelli G (1989) Influence of propranolol on platelet aggregation and thromboxane B2 production from platelet-rich plasma and whole blood. *Prostaglandins Leukot Essent Fat Acids* 36:1–7
- Fijnheer R, Pietersz RN, de Korte D, Gouwerok CW, Dekker WJ, Reesink HW, Roos D (1990) Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods. *Transfusion* 30:634–638
- Choukroun J, Adda F, Schoeffler C, Vervelle A (2001) Une opportunité en paro-implantologie: le PRF. *Implantodontie* 42:e62
- Toffler M (2014) Guided bone regeneration (GBR) using cortical bone pins in combination with leukocyte-and platelet-rich fibrin (L-PRF). *Compend Contin Educ Dent (Jamesburg, NJ : 1995)* 35:192–198.
- Lekovic V, Milinkovic I, Aleksic Z, Jankovic S, Stankovic P, Kenney E, Camargo P (2012) Platelet-rich fibrin and bovine porous bone mineral vs. platelet-rich fibrin in the treatment of intrabony periodontal defects. *J Periodontol* 47:409–417
- Shivashankar VY, Johns DA, Vidyantath S, Sam G (2013) Combination of platelet rich fibrin, hydroxyapatite and PRF membrane in the management of large inflammatory periapical lesion. *J Conserv Dent* 16:261
- Sammartino G, Dohan Ehrenfest DM, Carile F, Tia M, Bucci P (2011) Prevention of hemorrhagic complications after dental extractions into open heart surgery patients under anticoagulant therapy: the use of leukocyte- and platelet-rich fibrin. *The Journal of oral implantology* 37:681–690. <https://doi.org/10.1563/aaid-joi-d-11-00001>
- Hoaglin DR, Lines GK (2013) Prevention of localized osteitis in mandibular third-molar sites using platelet-rich fibrin. *International journal of dentistry* 2013:875380. <https://doi.org/10.1155/2013/875380>
- Suttapreyasri S, Leepong N (2013) Influence of platelet-rich fibrin on alveolar ridge preservation. *The Journal of craniofacial surgery* 24:1088–1094. <https://doi.org/10.1097/SCS.0b013e31828b6dc3>
- Yelamali T, Saikrishna D (2015) Role of platelet rich fibrin and platelet rich plasma in wound healing of extracted third molar sockets: a comparative study. *Journal of maxillofacial and oral surgery* 14:410–416. <https://doi.org/10.1007/s12663-014-0638-4>
- Anilkumar K, Geetha A, Umasudhakar, Ramakrishnan T, Vijayalakshmi R, Pameela E (2009) Platelet-rich-fibrin: a novel root coverage approach. *Journal of Indian Society of Periodontology* 13:50–54. <https://doi.org/10.4103/0972-124x.51897>
- Jankovic S, Aleksic Z, Klokkevold P, Lekovic V, Dimitrijevic B, Kenney EB, Camargo P (2012) Use of platelet-rich fibrin membrane following treatment of gingival recession: a randomized clinical trial. *The International journal of periodontics & restorative dentistry* 32:e41–e50
- Eren G, Tervahartiala T, Sorsa T, Atilla G (2015) Cytokine (interleukin-1beta) and MMP levels in gingival crevicular fluid after use of platelet-rich fibrin or connective tissue graft in the treatment of localized gingival recessions. *J Periodontol Res*. <https://doi.org/10.1111/jre.12325>
- Jain V, Triveni MG, Kumar AB, Mehta DS (2012) Role of platelet-rich-fibrin in enhancing palatal wound healing after free graft. *Contemporary clinical dentistry* 3:S240–S243. <https://doi.org/10.4103/0976-237x.101105>
- Kulkarni MR, Thomas BS, Varghese JM, Bhat GS (2014) Platelet-rich fibrin as an adjunct to palatal wound healing after harvesting a free gingival graft: a case series. *Journal of Indian Society of Periodontology* 18:399–402. <https://doi.org/10.4103/0972-124x.134591>
- Femminella B, Iaconi MC, Di Tullio M, Romano L, Sinjari B, D'Arcangelo C, De Ninis P, Paolantonio M (2016) Clinical comparison of platelet-rich fibrin and a gelatin sponge in the management of palatal wounds after epithelialized free gingival graft harvest: a randomized clinical trial. *J Periodontol* 87:103–113. <https://doi.org/10.1902/jop.2015.150198>
- Ajwani H, Shetty S, Gopalakrishnan D, Kathariya R, Kulloli A, Dolas RS, Pradeep AR (2015) Comparative evaluation of platelet-rich fibrin biomaterial and open flap debridement in the treatment of two and three wall intrabony defects. *Journal of international oral health : JIOH* 7:32–37
- di Lauro AE, Abbate D, Dell'Angelo B, Iannaccone GA, Scotto F, Sammartino G (2015) Soft tissue regeneration using leukocyte-platelet rich fibrin after excision of hyperplastic gingival lesions: two case reports. *J Med Case Rep* 9:252. <https://doi.org/10.1186/s13256-015-0714-5>
- Miron RJ, Fujioka-Kobayashi M, Bishara M, Zhang Y, Hernandez M, Choukroun J (2016) Platelet-Rich fibrin and soft tissue wound

- healing: a systematic review. *Tissue Eng B Rev*. <https://doi.org/10.1089/ten.TEB.2016.0233>
27. Medina-Porqueres I, Alvarez-Juarez P (2015) The efficacy of platelet-rich plasma injection in the management of hip osteoarthritis: a systematic review protocol. *Musculoskeletal care*. <https://doi.org/10.1002/msc.1115>
 28. Salamanna F, Veronesi F, Maglio M and Della Bella E (2015) New and emerging strategies in platelet-rich plasma application in musculoskeletal regenerative procedures: general overview on still open questions and outlook. 2015:846045. doi: <https://doi.org/10.1155/2015/846045>
 29. Albanese A, Licata ME, Polizzi B, Campisi G (2013) Platelet-rich plasma (PRP) in dental and oral surgery: from the wound healing to bone regeneration. *Immunity & ageing : I & A* 10:23. <https://doi.org/10.1186/1742-4933-10-23>
 30. Panda S, Doraiswamy J, Malaiappan S, Varghese SS, Del Fabbro M (2014) Additive effect of autologous platelet concentrates in treatment of intrabony defects: a systematic review and meta-analysis. *J Investig Clin Dent*. <https://doi.org/10.1111/jicd.12117>
 31. Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandalam U, Zhang Y, Ghanaati S, Choukroun J (2017) Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry? *Clin Oral Investig* 21:2619–2627. <https://doi.org/10.1007/s00784-017-2063-9>
 32. Abd El Raouf M, Wang X, Miusi S, Chai J, Mohamed AbdEl-Aal AB, Nefissa Helmy MM, Ghanaati S, Choukroun J, Choukroun E, Zhang Y and Miron RJ (2017) Injectable-platelet rich fibrin using the low speed centrifugation concept improves cartilage regeneration when compared to platelet-rich plasma. *Platelets*:1-9. doi: <https://doi.org/10.1080/09537104.2017.1401058>
 33. Wang X, Zhang Y, Choukroun J, Ghanaati S and Miron RJ (2017) Behavior of gingival fibroblasts on titanium implant surfaces in combination with either injectable-PRF or PRP. *Int J Mol Sci* 18. doi: <https://doi.org/10.3390/ijms18020331>
 34. Wang X, Zhang Y, Choukroun J, Ghanaati S, Miron RJ (2018) Effects of an injectable platelet-rich fibrin on osteoblast behavior and bone tissue formation in comparison to platelet-rich plasma. *Platelets* 29:48–55. <https://doi.org/10.1080/09537104.2017.1293807>
 35. Miron RJ, Chai J, Zheng S, Feng M, Sculean A, Zhang Y (2019) A novel method for evaluating and quantifying cell types in platelet rich fibrin and an introduction to horizontal centrifugation. *J Biomed Mater Res A*. <https://doi.org/10.1002/jbm.a.36734>
 36. Nunes CR, Roedersheimer M, Simske S, Luttes M (1995) Effect of microgravity, temperature, and concentration on fibrin and collagen assembly. *Microgravity science and technology* 8:125–130
 37. Ghanaati S, Booms P, Orłowska A, Kubesch A, Lorenz J, Rutkowski J, Landes C, Sader R, Kirkpatrick C, Choukroun J (2014) Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. *The Journal of oral implantology* 40:679–689. <https://doi.org/10.1563/aaid-joi-D-14-00138>
 38. Bielecki T, Dohan Ehrenfest DM, Everts PA, Wiczowski A (2012) The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: new perspectives. *Curr Pharm Biotechnol* 13: 1153–1162
 39. Martin P (1997) Wound healing—aiming for perfect skin regeneration. *Science* 276:75–81
 40. Barrick B, Campbell EJ, Owen CA (1999) Leukocyte proteinases in wound healing: roles in physiologic and pathologic processes. *Wound Repair Regen* 7:410–422
 41. Kobayashi E, Fluckiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, Miron RJ (2016) Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig* 20:2353–2360. <https://doi.org/10.1007/s00784-016-1719-1>
 42. Fujioka-Kobayashi M, Miron RJ, Hernandez M, Kandalam U, Zhang Y and Choukroun J (2016) Optimized platelet rich fibrin with the low speed concept: growth factor release, biocompatibility and cellular response. *J Periodontol*:1-17. doi: <https://doi.org/10.1902/jop.2016.160443>
- Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.